Precision medicine decision-making under pharmacogenomics in nursing: realizing value from limited evidence to scaled clinical pathways - Takeaways - MDSpire

Precision medicine decision-making under pharmacogenomics in nursing: realizing value from limited evidence to scaled clinical pathways

  • By

  • Guoling Qin

  • Xing Luo

  • Xuanrun Hao

  • Haiting Xiao

  • Kunpeng Wang

  • Houjun Pang

  • Meilin Li

  • Chuan Pi

  • Sha Yang

  • Qixiong Zhang

  • June 29, 2026

  • 0 min

Share

  • 1

    Pharmacogenomics (PGx) can reduce drug-gene mismatches in psychiatric prescribing, particularly for antidepressants and antipsychotics.

  • 2

    Current evidence supports PGx as an adjunctive tool for selected medications, but benefits vary and routine testing for all patients is not recommended.

  • 3

    Nurses play a crucial role in medication management, patient education, and monitoring, but implementation of PGx in routine care faces significant challenges.

  • 4

    Major organizations provide guidelines for PGx in prescribing, yet challenges include limited EHR integration and inconsistent clinician awareness.

  • 5

    The review aims to reposition PGx within psychiatric care pathways, emphasizing the nursing role in enhancing patient outcomes through informed care.

Original Source(s)

Precision medicine decision-making under pharmacogenomics in nursing: realizing value from limited evidence to scaled clinical pathways

  • by Guoling Qin, Xing Luo, Xuanrun Hao, Haiting Xiao, Kunpeng Wang, Houjun Pang, Meilin Li, Chuan Pi, Sha Yang, Qixiong Zhang

  • June 29, 2026

Related Content

Rethinking AI in youth mental health: promise, perils, and ethical integration

The burden of care, parenting stress, and navigating welfare services: parents’ everyday experiences of young children with autism spectrum disorder

Empowering healthier lifestyles: patterns of digital tool use, self-efficacy, and affective balance in IBD-patients and a community sample